ArticleEuropean journal of nuclear medicine and molecular imaging2018
Biological tumour volumes of gliomas in early and standard 20-40 min
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 50 citations in OpenAlex.
- Interobserver ground-truth variability limits performance of automated glioblastoma segmentation on [EJNMMI physics · 2025Article
- Pre-operative dual-time-point [European journal of nuclear medicine and molecular imaging · 2025Article
- Patterns of intersectional tumor volumes in T2-weighted MRI and [Scientific reports · 2024Observational
- Preparation and Preclinical Evaluation ofMolecules (Basel, Switzerland) · 2024Article
- Assessment of Brain Tumour Perfusion Using Early-PhaseMolecular imaging and biology · 2024Article
- Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET.Japanese journal of radiology · 2023Article
- Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas.Molecules (Basel, Switzerland) · 2023Review
- TSPO PET signal using [European journal of nuclear medicine and molecular imaging · 2023Article
- A Head-to-Head Comparison ofJournal of clinical medicine · 2022Article
- Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy.Advanced drug delivery reviews · 2022Review
- Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET.Cancer imaging : the official publication of the International Cancer Imaging Society · 2021Article
- The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.BMC cancer · 2021Article
- Glioma Biopsy Based on Hybrid Dual Time-Point FET-PET/MRI-A Proof of Concept Study.Frontiers in neurology · 2021Article
- TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlativeEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Comparison of [Molecular imaging and biology · 2020Article
- Approaches to PET Imaging of Glioblastoma.Molecules (Basel, Switzerland) · 2020Review
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2019Article
- FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.European journal of nuclear medicine and molecular imaging · 2019Article
- Prediction of IDH Status Through MRI Features and Enlightened Reflection on the Delineation of Target Volume in Low-Grade Gliomas.Technology in cancer research & treatment · 2019Article
- Voxel-wise analysis of dynamicEJNMMI research · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFor the clinical evaluation of O-(2-
methodsThe analysis included 245 patients with newly diagnosed, histologically verified glioma and a positive
resultsIn 52.2% of the patients (128/245), a significant difference in BTV of >20% between early and standard summation images was found. While 44.3% of WHO grade II gliomas (31 of 70) showed a significantly smaller BTV in the early summation images, 35.0% of WHO grade III gliomas (28/80) and 37.9% of WHO grade IV gliomas (36/95) had a significantly larger BTVs. Among IDH-wildtype gliomas, an even higher portion (44.4%, 67/151) showed significantly larger BTVs in the early summation images, which was observed in 5.3% (5/94) of IDH-mutant gliomas only: most of the latter had significantly smaller BTVs in the early summation images, i.e. 51.2% of IDH-mutant gliomas without 1p/19q codeletion (21/41) and 39.6% with 1p/19q codeletion (21/53).
conclusionBTVs delineated in early and standard summation images differed significantly in more than half of gliomas. While the standard summation images seem appropriate for delineation of LGG as well as IDH-mutant gliomas, a remarkably high percentage of HGG and, particularly, IDH-wildtype gliomas were depicted with significantly larger volumes in early summation images. This finding might be of interest for optimization of treatment planning (e.g. radiotherapy) in accordance with the individual IDH mutation status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.